balance equationreview2020-12-31
Difference 1286543000 exceeds tolerance 6790692.000. Presentation or filing-vintage differences need review.
Revenue
$1.18B
Fiscal year ended 2025-12-31Operating income
Unavailable
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31Healthcare Realty Trust Inc (HR) reported revenue of $1.18B and net income of -$246.07M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Healthcare Realty Trust Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Real Estate Investment Trusts.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.18B | $1.27B | $1.34B | $932.64M | $534.82M | $499.63M | $692.04M | $696.43M | $613.99M | $460.93M |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $123.65M | $101.92M |
| Net income | -$246.07M | -$654.48M | -$278.26M | $40.90M | $66.66M | $72.20M | $30.15M | $213.46M | $63.92M | $45.91M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 349.80M | shares 365.55M | shares 378.93M | shares 253.87M | shares 142.71M | shares 134.01M | shares 209.60M | shares 210.06M | shares 185.28M | shares 140.26M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-0.71 | $-1.81 | $-0.74 | $0.15 | $0.45 | $0.52 | $0.14 | $1.02 | $0.34 | $0.33 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $72.57M | $83.12M | $58.40M | $52.73M | $34.15M | $30.70M | $41.36M | $35.20M | $33.40M | $28.77M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $26.17M | $68.92M | $25.70M | $60.96M | $13.18M | $115.41M | $32.71M | $126.22M | $100.36M | $11.23M |
| Total assets | $9.21B | $10.65B | $12.64B | $13.85B | $4.26B | $6.79B | $6.64B | $6.19B | $6.45B | $3.75B |
| Current assets | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Total liabilities | $4.53B | $5.35B | $5.71B | $6.17B | $2.07B | $3.56B | $3.21B | $2.85B | $3.08B | $1.96B |
| Current liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Total equity incl. NCI | $4.67B | $5.30B | $6.92B | $7.68B | $2.19B | $1.95B | $1.90B | $3.33B | $3.36B | $1.78B |
| Temporary (mezzanine) equity | $3.25M | $4.78M | $3.87M | $2.01M | $0 | $0 | $0 | $6.54M | $6.74M | $4.65M |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $32.81M | $36.50M | $63.20M | $54.67M | $14.07M | $17.72M | $11.80M | $14.59M | $20.27M | $8.72M |
| Goodwill | Unavailable | $0 | $250.53M | $223.20M | $3.49M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | $3.91B | $4.66B | $4.99B | $5.35B | $1.80B | $3.03B | $2.75B | $2.54B | $2.78B | $1.77B |
| Accounts payable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $457.10M | $501.62M | $499.82M | $272.75M | $232.63M | $470.09M | $340.39M | $337.40M | $307.54M | $203.70M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | $710.83M | $900.92M | $349.14M | $1.63B | -$562.47M | -$555.17M | -$667.29M | $176.31M | -$2.46B | -$608.39M |
| Financing cash flow | -$1.21B | -$1.36B | -$884.22M | -$1.86B | $327.72M | $99.72M | $230.98M | -$498.74M | $2.24B | $400.78M |
| Net change in cash | -$42.74M | $43.22M | -$35.26M | $47.79M | -$2.13M | $14.65M | -$95.91M | $14.97M | $93.52M | -$3.92M |
| Stock-based compensation | $22.39M | $31.82M | $14.29M | $20.35M | $10.73M | $9.92M | $10.13M | $9.76M | $6.87M | $7.07M |
| Common dividends paid | $386.92M | $457.85M | $472.24M | $283.71M | $175.46M | $162.56M | $256.12M | $252.65M | $207.09M | $159.17M |
| Common share repurchases | $4.01M | $8.88M | $2.30M | $3.19M | $3.80M | $1.44M | $12.18M | $70.32M | $3.41M | $2.64M |
| Depreciation & amortization | $563.97M | $675.15M | $730.71M | $453.08M | $202.71M | $190.44M | $290.38M | $279.63M | $244.99M | $176.87M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.9% | 2.5% | 1.1% | 2.2% | 2.0% | 2.0% | 1.5% | 1.4% | 1.1% | 1.5% |
| Current ratio | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Revenue YoY growth | -6.9% | -5.6% | 44.1% | 74.4% | 7.0% | -27.8% | -0.6% | 13.4% | 33.2% | Unavailable |
| Net margin | -20.8% | -51.6% | -20.7% | 4.4% | 12.5% | 14.4% | 4.4% | 30.7% | 10.4% | 10.0% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | 0.84x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HR in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-08-01View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2019-12-31
Difference 1530635000 exceeds tolerance 6638749.000. Presentation or filing-vintage differences need review.